TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9389945

Group type: EXPERIMENTAL
Intervention: Detailed information sheet
Number of subjects: 200

Group type: COMPARATOR
Intervention: Minimal additional information
Number of subjects: 200
Study: 7707151

Group type: EXPERIMENTAL
Intervention: Self-measurement of blood pressure at home
Number of subjects: 44
Study: 2885064

Group type: EXPERIMENTAL
Intervention: Isoniazid (plus pyridoxine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29843226

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg over 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline control)
Number of subjects: 30
Study: 28404610

Group type: EXPERIMENTAL
Intervention: SARAH hand exercise programme
Number of subjects: 328

Group type: COMPARATOR
Intervention: Best practice usual care group
Number of subjects: 328
Study: 26687959

Group type: COMPARATOR
Intervention: Rituximab only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dulanermin and rituximab
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dulanermin only
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dulanermin (8 mg/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 weekly)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Dulanermin with rituximab
Number of subjects: 72
Study: 24191528

Group type: EXPERIMENTAL
Intervention: Adhesive tape (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thomas tube holder (Group B)
Number of subjects: 120
Study: 22075740

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 80
Study: 20020079

Group type: EXPERIMENTAL
Intervention: Mouthwash containing Triclosan and Gantrez
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (unlabeled toothpaste without Triclosan and Gantrez)
Number of subjects: 30
Study: 16957427

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Overall angioedema occurrence
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor arm
Number of subjects: 42418

Group type: EXPERIMENTAL
Intervention: Overall outcome
Number of subjects: 42418
Study: 15004821

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser treatment to one eye
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 26
Study: 11305631

Group type: EXPERIMENTAL
Intervention: Diet S (stearic acid, 19g/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diet P (palmitic acid)
Number of subjects: 13
Study: 9033244

Group type: EXPERIMENTAL
Intervention: 25 mg (0.25%) bupivacaine
Number of subjects: 97

Group type: COMPARATOR
Intervention: 12.5 mg (0.125%) bupivacaine
Number of subjects: 97
Study: 8511729

Group type: EXPERIMENTAL
Intervention: Bradykinin (1.9 mumol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine (1.9 mumol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study: 30265585

Group type: EXPERIMENTAL
Intervention: Topical E6005
Number of subjects: 72
Study: 29667099

Group type: EXPERIMENTAL
Intervention: Continuing NSAIDs and DMARDs (group 1)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tapering NSAIDs and DMARDs by 50% (group 2)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Discontinuing NSAIDs and DMARDs (group 3)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: High ASDAS‐CRP at baseline
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Drug discontinuation
Number of subjects: 108
Study: 27343254

Group type: EXPERIMENTAL
Intervention: Tailored interactive multimedia computer program (IMCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailoring modules encouraging adherence to the tailored screening recommendation and discussion with the patient's PCP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Better self-reported physical health and increased patient activation
Number of subjects: 0
Study: 24793701

Group type: EXPERIMENTAL
Intervention: Intermittent reinflation (IR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study: 22642352

Group type: EXPERIMENTAL
Intervention: Negative arousing sounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral sounds
Number of subjects: 0
Study: 20346777

Group type: EXPERIMENTAL
Intervention: 0.18% sodium hyaluronate ophthalmic solution (Rejena, Vismed)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 444
Study: 16915361

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitisation and Reprocessing (EMDR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Imaginal Exposure and Cognitive Restructuring (E+CR)
Number of subjects: 48
Study: 16198883

Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging (DTI) M-mode analysis of the anterior mitral leaflet
Number of subjects: 60
Study: 11818177

Group type: EXPERIMENTAL
Intervention: Provider reminder with in-service training during INT1
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Hospital-wide intervention (INT2)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group during INT1
Number of subjects: 534
Study: 10368336

Group type: EXPERIMENTAL
Intervention: 8 g glutamine in 330 ml glucose polymer solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral glutamine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingestion of glutamine and glucose polymer together
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8 g glutamine in 330 ml placebo
Number of subjects: 0
Study: 8789313

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B and C patients
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 98
Study: 2305417

Group type: EXPERIMENTAL
Intervention: S(+)‐disopyramide
Number of subjects: 6

Group type: COMPARATOR
Intervention: R(‐)‐disopyramide
Number of subjects: 6
Study: 6773161

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 9
Study: 30776898

Group type: EXPERIMENTAL
Intervention: G-CPR (resuscitation-retraining programme)
Number of subjects: 79

Group type: COMPARATOR
Intervention: G-Stan (standard programme)
Number of subjects: 79
Study: 26946616

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbs for tonifying Qi and kidney, and replenishing spleen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo granules
Number of subjects: 60
Study: 24784832

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) snack (0.4 g carbohydrate/kg body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High Glycemic Index (HGI) snack (0.4 g carbohydrate/kg body mass)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both meal types (LGI and HGI)
Number of subjects: 10
Study: 22472562

Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 69
Study: 20823895

Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol monthly (1600 U/day)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 50,000 U oral cholecalciferol bimonthly (800 U/day)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 17427923

Group type: EXPERIMENTAL
Intervention: Carrying an infant in one's arms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Using a tool to sling the infant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrying a baby in one's arms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wider bi-trochanteric width
Number of subjects: 0
Study: 15834750

Group type: EXPERIMENTAL
Intervention: Vitek 2 system (bioMerieux, Marcy l'Etoile, France)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional methods (overnight methods for identification and susceptibility testing)
Number of subjects: 0
Study: 12495243

Group type: EXPERIMENTAL
Intervention: Strength training twice per week (n = 20)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Strength training once per week (n = 22)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 55
Study: 9523803

Group type: EXPERIMENTAL
Intervention: 1.5% mepivacaine (45 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lidocaine (60 mg)
Number of subjects: 60
Study: 7892823

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 1829
Study: 2692654

Group type: EXPERIMENTAL
Intervention: Perioperative cyclophosphamide
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Long-term tamoxifen
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide and tamoxifen
Number of subjects: 2230
Study: 202425

Group type: EXPERIMENTAL
Intervention: Oral magnesium oxide
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30816107

Group type: EXPERIMENTAL
Intervention: Ultrasound with developing line
Number of subjects: 77

Group type: COMPARATOR
Intervention: Traditional ultrasound
Number of subjects: 77
Study: 30338528

Group type: EXPERIMENTAL
Intervention: Emotionally provocative clip
Number of subjects: 158

Group type: COMPARATOR
Intervention: Emotionally neutral clip
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Emotionally provocative clip (remotely)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Emotionally neutral clip (remotely)
Number of subjects: 158
Study: 26369888

Group type: EXPERIMENTAL
Intervention: Higher tidal volume (20 ml kg(‐1) ideal body weight)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard tidal volume (10 ml kg(‐1) ideal body weight)
Number of subjects: 33
Study: 25179854

Group type: EXPERIMENTAL
Intervention: Group-mediated cognitive behavioral exercise intervention (GMCB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional center-based exercise therapy (TRAD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GMCB
Number of subjects: 80

Group type: COMPARATOR
Intervention: TRAD
Number of subjects: 80
Study: 22877317

Group type: EXPERIMENTAL
Intervention: Modified Mechanical Post-Conditioning (MMPOC)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 20820932

Group type: EXPERIMENTAL
Intervention: CRD-UFA (47 g SFA/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRD-SFA (86 g/d SFA)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Both CRD
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRD-SFA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CRD-UFA
Number of subjects: 8
Study: 17001492

Group type: EXPERIMENTAL
Intervention: 12-week home-based walking intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (wait-list)
Number of subjects: 36
Study: 16999714

Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (GH) and chondroitin sulfate (CS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucosamine sulfate (GS), glucosamine hydrochloride (GH), and chondroitin sulfate (CS)
Number of subjects: 0
Study: 12589390

Group type: EXPERIMENTAL
Intervention: Caffeine 150 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 10224952

Group type: EXPERIMENTAL
Intervention: Maudsley Obsessional Compulsive Inventory (MOCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOCI
Number of subjects: 0
Study: 8546475

Group type: COMPARATOR
Intervention: Granisetron alone (40 micrograms/kg)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Combination of granisetron and methylprednisolone (MP: 10 mg/kg)
Number of subjects: 95
Study: 2070983

Group type: EXPERIMENTAL
Intervention: New low-sodium cleansing solution
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard polyethylene glycol solution
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Comparison of both solutions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Saltiness perception
Number of subjects: 78
Study: 6403021

Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 20

Group type: COMPARATOR
Intervention: prajmalium bitartrate
Number of subjects: 20
Study: 31077127

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CRT) without surgery (Group 1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) + abdominoperineal resection (APR) (Group 2)
Number of subjects: 18
Study: 28530840

Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg subcutaneously every 4 weeks or every 8 weeks)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Benralizumab (every 4 weeks)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Benralizumab (every 8 weeks)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Benralizumab (both regimens)
Number of subjects: 369
Study: 25748471

Group type: EXPERIMENTAL
Intervention: DB-ACLR using footprint remnant procedure (EF group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: DB-ACLR using bony landmark procedure (BL group)
Number of subjects: 72
Study: 23432408

Group type: EXPERIMENTAL
Intervention: L. casei strain Shirota fermented milk
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 21352464

Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 77
Study: 19525832

Group type: EXPERIMENTAL
Intervention: Iliac crest autograft (group A, n = 32)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Titanium mesh cages (group B, n = 33)
Number of subjects: 65
Study: 17727393

Group type: EXPERIMENTAL
Intervention: Talnetant 25 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Talnetant 100 mg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 15453971

Group type: EXPERIMENTAL
Intervention: Elicitation tasks and auditory priming study
Number of subjects: 4
Study: 12408444

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 9680900

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (0.05%)‐sodium fluoride (0.04%)‐strontium (100 ppm as SrCl2) rinsing solution (CXFSr)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 18
Study: 7844233

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (150 mg or 300 mg daily) starting from day 13 of HRT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin starting from day 1 of HRT
Number of subjects: 99

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 99
Study: 2810695

Group type: EXPERIMENTAL
Intervention: Ulinastatin 12000 U.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ulinastatin 6000 U.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 1097194

Group type: EXPERIMENTAL
Intervention: 5 mg indapamide daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: 100 mg chlorthalidone daily
Number of subjects: 38
Study: 30317902

Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation
Number of subjects: 0
Study: 30691768

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 44

Group type: COMPARATOR
Intervention: Friction massage
Number of subjects: 44
Study: 28697102

Group type: EXPERIMENTAL
Intervention: 2 g secnidazole
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: 1 g secnidazole
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 25858178

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring in CBT (12-16 sessions)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Brief treatment programme (3 sessions of breathing retraining and education)
Number of subjects: 201
Study: 23686891

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 1.5 ng/mL (R1.5)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Remifentanil at effect-site concentration of 2 ng/mL (R2)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Remifentanil at effect-site concentration of 1 ng/mL (R1)
Number of subjects: 105
Study: 21401801

Group type: EXPERIMENTAL
Intervention: Group A (3‐monthly spirometry with medical review)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Group B (spirometry only before and after the trial)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Group C (usual care)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Group A vs Groups B + C
Number of subjects: 195
Study: 19824278

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TF)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 5
Study: 18060626

Group type: EXPERIMENTAL
Intervention: Conventional therapy + atorvastatin (10 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 48
Study: 15544079

Group type: EXPERIMENTAL
Intervention: Sliding screw device combined with calcium‐phosphate cement for augmentation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sliding screw device alone (Controls)
Number of subjects: 21
Study: 11227321

Group type: EXPERIMENTAL
Intervention: Psychodynamic oriented psychotherapy in addition to standardized medical treatment
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standardized medical treatment (Control group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Psychodynamic oriented psychotherapy
Number of subjects: 108
Study: 9662680

Group type: EXPERIMENTAL
Intervention: Exercise Only
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise/Study
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Study Only
Number of subjects: 14
Study: 7920211

Group type: EXPERIMENTAL
Intervention: Beta-carotene (30 mg/day) and vitamin A (25,000 international units/day)
Number of subjects: 2319

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 2319
Study: 2112188

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (IMV)
Number of subjects: 432
Study: 7537

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 31150601

Group type: COMPARATOR
Intervention: US-guided standard subacromial injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dual-target injection (subacromial bursa plus proximal biceps long-head tendon)
Number of subjects: 60
Study: 28439629

Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lateral Approach (LA)
Number of subjects: 70
Study: 24919604

Group type: EXPERIMENTAL
Intervention: Wheat fibre (15 g day⁻¹)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inulin (15 g day⁻¹)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (refined grain, 15 g day⁻¹)
Number of subjects: 10
Study: 23212552

Group type: EXPERIMENTAL
Intervention: Impella-2.5-percutaneous left-ventricular assist device
Number of subjects: 120
Study: 20950324

Group type: EXPERIMENTAL
Intervention: Alternating frequency (AE) stimulation
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low frequency (LE) stimulation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham control group (SE)
Number of subjects: 27
Study: 19634943

Group type: EXPERIMENTAL
Intervention: Delayed extinction (extinction training 1 day later)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate extinction (extinction training 5 min later)
Number of subjects: 0
Study: 17531699

Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 multifocal IOL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Array SA40 multifocal IOL
Number of subjects: 50
Study: 15362934

Group type: EXPERIMENTAL
Intervention: 4 g daily of 95% ethyl esters of eicosapentaenoic acid (EPA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oleic acid (OA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 28

Group type: COMPARATOR
Intervention: OA
Number of subjects: 28
Study: 10631623

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluoxetine and Paroxetine (comparison)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sertraline and Venlafaxine (comparison)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fluoxetine and Venlafaxine
Number of subjects: 12
Study: 8725855

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol . kg-1 . min-1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 11
Study: 1305301

Group type: EXPERIMENTAL
Intervention: Ultraconservative, sealed composite resin restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultraconservative, localized, sealed amalgam restorations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional, unsealed amalgam restorations
Number of subjects: 0